Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

Chronic pain is presented as a key entry point into opioid related harm in the United States, with policy and regulation shaping how patients transition from prescribed opioids to illicit supply when care becomes unstable. The article argues that while opioids can be valuable in medical settings, stigma, fear of legal consequences, fragmented care, and abrupt tapering can increase risk. It claims many patients do not immediately move to heroin or illicitly manufactured fentanyl, but instead first seek illicit pharmaceutical opioids like OxyContin, driven by familiarity and cost constraints, before more potent illicit options become more accessible. Psychedelics are proposed as a potential missing middle path in pain care. The text links emerging evidence to mechanisms such as modulation of central sensitization, altered emotional processing, inflammation effects, and reorganization of rigid brain networks. It also highlights case level signals where structured psilocybin based approaches alongside adjunctive therapies reportedly reduced pain in phantom limb pain and refractory complex regional pain syndrome, with the broader implication that safer, adjunctive psychedelic assisted models could reduce pressure toward illicit markets and overdoses.